Trials For Preparation And Evaluation Of Inactivated Tissue Culture Newcastle Disease Vaccine From Recent Isolate

The present study was undertaken to development of BHK-21 cell adapted inactivated vaccine of Newcastle disease virus (NDVgenotype VII) from the field isolate from broiler chicken in Egypt during 2015-2016. The isolatesof El-Giza/2015were classified by sequencing as velogenic NDV genotype VII d contains F protein cleavage site motifs (112RRQKRF117). Such virus was propagated in the BHK-21 cell line. and cell adapted virus was confirmed as NDV by reverse transcription-polymerase chain reaction (RT-PCR) using fusion gene-specific primers and used to develop inactivated vaccine adjuvanted with Montanide IMS 1313.Potency test revealed that Vaccinated chicks with 0.5ml of prepared NDV vaccine exhibited HI antibody titer of 8.6 log2 three weeks post vaccination with the highest titer (10.6 log2/ml) at the 6th-week post vaccination, and 3rd weeks post challenge test. Protective antibodies values were persisting till 12th weeks post vaccination. All chicken groups vaccinated with both prepared inactivated tissue culture vaccine using ISA 1313 and VSVRI inactivated ISA70 adjuvant vaccines were passed challenge test (97.5%,97%,96% protective efficiency to SPF chickens) against the isolated virulent NDV, while the control group could not provide any protective efficiency. The present study indicated that, BHK-21 cell adapted recent isolated NDV inactivated vaccine produced a satisfactory antibodies titre that efficient in control of the disease in Egypt.